AstraZeneca (NASDAQ: AZN) reported Q4 EPS of $1.67, $0.94 better than the analyst estimate of $0.73. Revenue for the quarter came in at $12.01 billion versus the consensus estimate of $10.96 billion.

Commenting on 2022 growth guidance, the company expects the following: "Total Revenue is expected to increase by a high teens percentage Core EPS is expected to increase by a mid-to-high twenties percentage."

For earnings history and earnings-related data on AstraZeneca (AZN) click here.